Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma

Overview of attention for article published in Journal of Clinical Oncology, May 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news: 12 news outlets
blogs: 1 blog

twitter: 57 X users
guideline: 4 clinical guideline sources

Readers on

mendeley: 134 Mendeley

So far, Altmetric has seen 71 X posts from 57 X users, with an upper bound of 294,983 followers.

Burkitt's lymphoma Stage IV, Fit 35 yr old Bone marrow involved CSF Flowcytometry negative DA-REPOCH data (JCO 2020) indicates this group doesn't do well (4 yr EFS 66% vs 92%) https://t.co/9kluVuDuR2 How do you treat?

RT @mtmdphd: Is Dose-adjusted EPOCH-R Enough in Burkitt Lymphoma? [Oct 6, 2020] Brad Kahl, MD - The Hematologist @ASH_hematology https://t…

Is Dose-adjusted EPOCH-R Enough in Burkitt Lymphoma? [Oct 6, 2020] Brad Kahl, MD - The Hematologist @ASH_hematology https://t.co/2djysI19kK #lymsm RE: @RoschewskiMD et al. JCO @ASCO_pubs https://t.co/vvTcK2XXTh #lymsm

Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma [May 26, 2020] @RoschewskiMD et al. JCO @ASCO_pubs https://t.co/IfKQyjvfvO #lymsm

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 67 additional X posts.